MedTrace Logo

Towards a Food Ingredient Clinically Proven to Benefit Gut Health: Novel RG-I Variants

NCT06081972 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-07-16

No results posted yet for this study

Summary

The aim of this study is to determine, quantify and understand the potential prebiotic effects of RG-I variants via microbiota modulation. The anti-inflammatory potential effects of these variants will also be investigated.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Maltodextrin

During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.

DIETARY_SUPPLEMENT

Chicory RG-I

During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.

DIETARY_SUPPLEMENT

Carrot RG-I

During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.

Sponsors & Collaborators

  • NutriLeads B.V. (Wageningen, The Netherlands)

    collaborator UNKNOWN

  • ProDigest (Ghent, Belgium)

    collaborator UNKNOWN

  • Ambiotis (Toulouse, France)

    collaborator UNKNOWN

  • Örebro University, Sweden

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2024-05-30
Completion
2024-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06081972 on ClinicalTrials.gov